HIV Neutralizing Antibodies: Development and Association with HIV Related Disease

References

• Weiss R A, Clapham P R, Cheingsong-Popov R, Dalgleish A G, Carne C A, Weller I VD, Tedder R S. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature 1985; 316: 69–72
   PubMed Web of Science ®Google Scholar
• Robert-Guroff M, Brown M, Gallo R C. HTLV-III neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature 1985; 316: 72–74
   PubMed Web of Science ®Google Scholar
• Groopman J E, Benz P M, Ferriani R, Mayer K, Allan J D, Weymouth L A. Characterization of serum neutralization response to the human immunodeficiency virus (HIV). AIDS Res Hum Retrovir 1987; 3: 71–85
   PubMed Web of Science ®Google Scholar
• Prince A M, Pascual D, Kosolapov L B, Kurokawa D, Baker L, Rubinstein P. Prevalence, clinical significance, and strain specificity of the neutralizing antibody to the human immunodeficiency virus. J Infect Dis 1987; 156: 268–272
   PubMed Web of Science ®Google Scholar
• Weber J N, Weiss R A, Roberts C, Weller J, Tedder R S, Clapham P R, Parker D, Duncan J, Came C, Pinching A J, Cheingsong-Popov R. Human immunodeficiency virus infection in two cohorts of homosexual men: neutralizing sera and association of anti-gag antibody with prognosis. Lancet 1987; 1: 119–122
   PubMed Web of Science ®Google Scholar
• Robert-Guroff M, Giardina P J, Robey W G, Jennings A M, Naugle C J, Akbar A N, Grady R W, Hilgartner M V. HTLV-III neutralizing antibody development in transfusion-dependent seropositive patients with B-thalassemia. J Immunol 1987; 138: 3731–3736
   PubMed Web of Science ®Google Scholar
• Weymouth L A, Hammer S M, Gillis J M, Benz P M, Ferriani R, Groopman J E. Isolation of human immunodeficiency virus and serum neutralizing antibody. Lancet 1986; 1: 1158–1159
   PubMedGoogle Scholar
• Wendler I, Bienzle U, Hunsmann G. Neutralizing antibodies and the course of HIV-induced disease. AIDS Res Hum Retrovir 1987; 3: 157–163
   PubMed Web of Science ®Google Scholar
• Weber J N, Wadsworth J, Rogers L A, Moshtael O, Scott K, McManus T, Berrie E, Jeffries D J, Harris J RW, Pinching A J. Three year prospective study of HTLV-III/LAV infection in homosexual men. Lancet 1986; 1: 1179–1182
   PubMed Web of Science ®Google Scholar
• Goedert J J, Biggar R J, Weiss S H, Eyster M E, Melby M, Wilson S, Ginzburg H M, Grossman R J, DiGiola R A, Sanchez W C, Giron J A, Ebbesen P, Gallo R C, Blattner W A. Three-year incidence of AIDS in five cohorts of HTLV-III infected risk groups members. Science 1986; 231: 992–995
   PubMed Web of Science ®Google Scholar
• Gerstoft J, Petersen C S, Kroon S, Ullman S, Lindhardt Bø, Hofmann B, Gaub J, Dickmeiss E. The immunological and clinical outcome of HIV infection: 31 months of follow-up in a cohort of homosexual men. Scand J Infect Dis 1987; 19: 503–509
   PubMed Web of Science ®Google Scholar
• Francis D P, Petricciani J C. The prospects for and pathways toward a vaccine for AIDS. N Engl J Med 1985; 313: 1586–1590
   PubMed Web of Science ®Google Scholar
• Schüpbach J, Haller O, Vogt M, Lüthy R, Joller H, Oelz O, Popovic M, Sarngardharan M G, Gallo R C. Antibodies to HTLV-III in Swiss patients with AIDS and pre–AIDS and in groups at risk for AIDS. N Engl J Med 1985; 312: 265–270
   PubMed Web of Science ®Google Scholar
• Lange J MA, Paul D A, Huisman H G, de Wolf F, van der Berg H, Coutinho R A, Danner S A, van der Noordaa J, Goudsmit J. Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. Br Med J 1986; 293: 1459–1462
   PubMed Web of Science ®Google Scholar
• Pedersen C, Nielsen C M, Vestergaard B F, Gerstoft J, Krogsgaard K, Nielsen J O. Temporal relation of antigenaemia and loss of antibodies to the core antigen to the development of AIDS or ARC in patients with HIV infection. Br Med J 1987; 295: 567–569
   PubMed Web of Science ®Google Scholar
• Gaub J, Pedersen C, Poulsen A G, Mathiesen L R, Ulrich K, Lindhardt Bø, Faber V, Gerstoft J, Hofmann B, Lernestedt J O, Nielsen C M, Nielsen J O, Platz P. The effect of Foscarnet (Phos-phonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. AIDS 1987; 1: 27–33
   PubMed Web of Science ®Google Scholar
• McDougal J S, Cort S P, Kennedy M S, Cabridilla C D, Feorino P M, Francis D P, Micks D, Kalyanaraman V S, Martin L S. Immunoassay for the detection and quantitation of infectious human retrovirus, lymphadenopathy-associated virus (LAV). J Immunol Methods 1985; 76: 171–183
   PubMed Web of Science ®Google Scholar
• Poiesz B J, Ruscetti F W, Gazdar A F, Bunn P A, Minna J D, Gallo R C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77: 7415–7419
   PubMed Web of Science ®Google Scholar
• Reed L J, Muench H. A simple method of estimating fifty percent endpoint. Am J Hyg 1938; 27, 493—497
   Google Scholar
• Lindhardt B, Ulrich K, Ryder L, Dickmeiss E, Sørensen H, Jørgensen J, Jersild C, Grunnet N. HTLV-III antibody testing in three Danish blood banks. Vox Sang 1986; 51: 9–14
   PubMed Web of Science ®Google Scholar
• CDC. Classification System for Human T-lymphotropic Virus III/Lymphadenopathy-associated Virus Infections. MMWR 1986; 35(20)334–339
   PubMedGoogle Scholar
• Arendrup M, Lindhardt Bø, Krogsgaard K, Gaub J, Nielsen J O. Copenhagen Hepatitis Acuta Programme. Antibody to HIV in patients with acute hepatitis B in the period 1975–1984. Scand J Infect Dis 1987; 19: 167–172
   PubMed Web of Science ®Google Scholar
• Starcich B R, Hahn B H, Shaw G M, NcNelly P D, Modrow S, Wolf H, Parks E S, Parks W P, Josephs S F, Gallo R C, Wong-Staal F. Identification and characterization of conserved and variable regions in the envelope gene of HTLV–III/LAV, the retrovirus of AIDS. Cell 1986; 45: 637–648
   PubMed Web of Science ®Google Scholar
• Alizon M, Wain-Hobson S, Montagnier L, Sonigo P. Genetic variability of the AIDS virus: Nucleotide sequence analysis of two isolates from African patients. Cell 1986; 46: 63–74
   PubMed Web of Science ®Google Scholar
• Weiss R A, Clapman P R, Weber J N, Dalgleish A G, Lasky L A, Berman P W. Variable and conserved neutralization antigens of human immunodeficiency virus. Nature 1986; 324: 572–575
   PubMed Web of Science ®Google Scholar
• Ranki A, Weiss S H, Valle S-L, Antonen J, Krohn K JE. Neutralizing antibodies in HIV (HTLV-III) infection: correlation with clinical outcome and antibody response against different viral proteins. Clin Exp Immunol 1987; 69: 231–239
   PubMed Web of Science ®Google Scholar
• Lasky L A, Groopman J E, Fennie C W, Benz P M, Capon P J, Dowbenko D J, Nakamura G R, Nunes W M, Renz M E, Berman P W. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science 1986; 233: 209–212
   PubMed Web of Science ®Google Scholar
• Robey W G, Arthur L O, Matthews T J, Langlois A, Copeland T D, Lerche N W, Oroszlan S, Bolognesi D P, Gilden R V, Fishinger P J. Prospect for prevention of human immunodeficiency virus infection. Purified 120 kD envelope glycoprotein induces neutralizing antibody. Proc Natl Acad Sci USA 1986; 83: 7023–7027
   PubMed Web of Science ®Google Scholar